- Conditions
- Chronic Pain Syndrome
- Interventions
- MBSR treatment
- Behavioral
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 381 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1825–1848
of 12,241
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Insomnia Disorder
- Interventions
- Daridorexant 25 mg, Daridorexant 50 mg, Placebo
- Drug · Other
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 930 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 36
- States / cities
- Anniston, Alabama • Birmingham, Alabama • Little Rock, Arkansas + 33 more
- Conditions
- Oligometastatic Prostate Cancer (OMPC)
- Interventions
- AAA617, piflufolastat (18F), gallium (68Ga) gozetotide (25μg)
- Drug
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 100 Years · Male only
- Enrollment
- 450 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2031
- U.S. locations
- 39
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Palo Alto, California + 30 more
- Conditions
- Immunoglobulin A Nephropathy, Glomerular Disease, IgAN
- Interventions
- Dose-Placebo, Low Dose-VIS649, Medium Dose-VIS649, High Dose-VIS649
- Drug
- Lead sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 155 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 17
- States / cities
- Birmingham, Alabama • Los Angeles, California • Oxnard, California + 13 more
- Conditions
- Pelvic Floor Disorders, Pelvic Pain, Pelvic Organ Prolapse, Pelvic Floor Muscle Weakness, Pelvic Pain Syndrome
- Interventions
- Bloom Pod
- Device
- Lead sponsor
- Sword Health, SA
- Industry
- Eligibility
- 18 Years to 99 Years · Female only
- Enrollment
- 50,000 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2022 – 2032
- U.S. locations
- 1
- States / cities
- Draper, Utah
- Conditions
- Multiple Myeloma, Non-Hodgkins Lymphoma
- Interventions
- Plerixafor
- Drug
- Lead sponsor
- Shi, Patricia, M.D.
- Individual
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Pregnancy, Down Syndrome, Edwards Syndrome, Patau Syndrome, Turners Syndrome
- Interventions
- Not listed
- Lead sponsor
- Verinata Health, Inc.
- Industry
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 3,000 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2012
- U.S. locations
- 26
- States / cities
- San Diego, California • Atlanta, Georgia • Chicago, Illinois + 22 more
- Conditions
- Post-Lumbar Puncture Headache
- Interventions
- Epidural Blood Patch
- Other
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 65 Years · Female only
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Multiple Myeloma
- Interventions
- Panobinostat Capsules, Bortezomib Injection, Dexamethasone tablets
- Drug
- Lead sponsor
- pharmaand GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 248 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 9
- States / cities
- Fayetteville, Arkansas • Los Angeles, California • Fort Collins, Colorado + 6 more
- Conditions
- Multiple Myeloma
- Interventions
- Belantamab mafodotin, Bortezomib, Lenalidomide, Dexamethasone
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 118 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2028
- U.S. locations
- 3
- States / cities
- Westwood, Kansas • Charlotte, North Carolina • Madison, Wisconsin
- Conditions
- Systemic Lupus Erythematosus
- Interventions
- TEACH
- Behavioral
- Lead sponsor
- Michigan State University
- Other
- Eligibility
- 12 Years to 22 Years
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Grand Rapids, Michigan
- Conditions
- Down Syndrome, Trisomy 21
- Interventions
- Not listed
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 6 Months to 89 Years
- Enrollment
- 2,500 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2016 – 2036
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Secondary Hypogonadism
- Interventions
- Androxal (enclomiphene citrate), Testosterone
- Drug
- Lead sponsor
- Repros Therapeutics Inc.
- Industry
- Eligibility
- 18 Years to 65 Years · Male only
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011
- U.S. locations
- 2
- States / cities
- Houston, Texas • San Antonio, Texas
- Conditions
- Polycystic Kidney, Autosomal Dominant
- Interventions
- Metformin, Placebo
- Drug · Other
- Lead sponsor
- Kyongtae Ty Bae, M.D., Ph.D.
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 97 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Boston, Massachusetts
- Conditions
- Multiple Myeloma
- Interventions
- carfilzomib, pegylated liposomal doxorubicin (PLD), Dexamethasone
- Drug
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2018
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Kidney Diseases, Diabetic Nephropathies, Glomerulosclerosis, Focal Segmental, Nephrosis, Lipoid, Urologic Diseases, Diabetes Complications, Diabetes Mellitus, Endocrine System Diseases, Glomerulonephritis, Nephritis, Nephrosis
- Interventions
- GFB-887, Placebo
- Drug
- Lead sponsor
- Goldfinch Bio, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 96 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 74
- States / cities
- Birmingham, Alabama • Mesa, Arizona • Scottsdale, Arizona + 66 more
- Conditions
- Pancreatic Neuroendocrine Tumor, Pancreas Cancer
- Interventions
- cytoreductive surgery, Lutathera - a small molecule used in Peptide Receptor Radionuclide Therapy (PRRT), Peptide receptor radionuclide therapy (PRRT)
- Procedure · Drug
- Lead sponsor
- University of Chicago
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Opioid Dependency
- Interventions
- Probuphine (buprenorphine implant)
- Drug
- Lead sponsor
- Titan Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- North Miami, Florida
- Conditions
- Relapsed or Refractory Multiple Myeloma
- Interventions
- mezigdomide, Pomalidomide, Bortezomib, Dexamethasone
- Drug
- Lead sponsor
- Celgene
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 810 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2033
- U.S. locations
- 56
- States / cities
- Los Alamitos, California • San Diego, California • West Hollywood, California + 50 more
- Conditions
- Cancer, Quality of Life, Anxiety, Depression, Hope, Coping Skills, Communication
- Interventions
- Promoting Resilience in Stress Management (PRISM)
- Behavioral
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 12 Years to 24 Years
- Enrollment
- 269 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 5
- States / cities
- Los Angeles, California • Boston, Massachusetts • Pittsburgh, Pennsylvania + 2 more
- Conditions
- Prostate Cancer
- Interventions
- Clinical Order Check, Academic Detailing, Audit and Feedback
- Behavioral
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- Not listed
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 11
- States / cities
- Palo Alto, California • West Los Angeles, California • West Haven, Connecticut + 8 more
- Conditions
- Prostate Cancer
- Interventions
- Degarelix
- Drug
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 26
- States / cities
- Homewood, Alabama • Anchorage, Alaska • Anaheim, California + 23 more
- Conditions
- Acute Leukemia, Chronic Myeloproliferative Disease, Chronic Lymphoproliferative Disease, Multiple Myeloma, Lymphoma, Poor-risk Myelodysplasia (MDS)
- Interventions
- ZIO-101 (Darinaparsin)
- Drug
- Lead sponsor
- Alaunos Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2008
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Subarachnoid Aneurysm Hemorrhage, Subarachnoid Hemorrhage, Aneurysmal
- Interventions
- Not listed
- Lead sponsor
- University of Alberta
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 500 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 1
- States / cities
- Richmond, Virginia